Telix Pharmaceuticals (TLX) Receivables - Net (2023 - 2025)

Telix Pharmaceuticals (TLX) has 3 years of Receivables - Net data on file, last reported at $129.2 million in Q4 2025.

• In Q4 2025, Receivables - Net rose 41.47% year-over-year to $129.2 million; the TTM figure through Dec 2025 stood at $129.2 million (up 41.47% YoY), while the FY2025 annual figure was $129.2 million, up 48.63% from the prior year.
• Receivables - Net advanced to $129.2 million in Q4 2025, from $91.3 million in the prior quarter.
• Across five years, Receivables - Net topped out at $129.2 million in Q4 2025 and bottomed at $42.2 million in Q4 2023.
• A 3-year average of $87.6 million and a median of $91.3 million in 2024 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2024 — Receivables - Net jumped 116.58% — and 2025, when it surged 41.47%.
• Year by year, Receivables - Net stood at $42.2 million in 2023, then surged by 116.58% to $91.3 million in 2024, then soared by 41.47% to $129.2 million in 2025.
• The last three Receivables - Net figures came in at $129.2 million (Q4 2025), $91.3 million (Q4 2024), and $42.2 million (Q4 2023), per Business Quant data.

Peer Comparison